HERON THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
HERON THERAPEUTICS INC. - More news...
HERON THERAPEUTICS INC. - More news...
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
- Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
- Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
- Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
- Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
- Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
- Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
- Heron Therapeutics Announces Cost Reduction Plan and Restructuring
- Heron Therapeutics Announces $30 Million Private Placement Financing
- Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
- Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
- Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
- Heron Therapeutics Announces Commercial Leadership Changes
- Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
- Heron Therapeutics Announces New CEO and Board Chairman
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
- Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
- Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults
- Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference
- Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital
- Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
- Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF
- Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference
- Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
